PURPOSE The regimens approved for the treatment of advanced head and neck squamous
cell carcinoma are accessible to only 1%-3% of patients in low-and middle-income countries …

Head and neck squamous cell carcinoma (HNSCC) is a relatively common cancer (1). While
many patients with locally advanced disease are cured with some combination of surgery …

Background Locoregionally advanced, recurrent, and metastatic squamous cell carcinomas
of the head and neck (SCCHN) remain difficult to treat disease entities, in which systemic …

Importance There remains an unmet need to improve clinical outcomes in patients with
recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) …

Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of
chemotherapy at the primary analysis of randomized, open‐label, phase 3 CheckMate 141 …

PURPOSE CheckMate 651 (ClinicalTrials. gov identifier: NCT02741570) evaluated first-line
nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus …

Background: No large-scale retrospective studies have examined the efficacy and safety of
nivolumab. Objective: This retrospective study aimed to investigate the efficacy and safety of …

Abstract Purposeof Review Head and neck cancer (HNC) comprises a group of
malignancies, amongst which squamous cell carcinoma accounts for more than 90% of the …

Background Patients with recurrent or metastatic squamous-cell carcinoma of the head and
neck after platinum chemotherapy have a very poor prognosis and limited therapeutic …

Importance Nivolumab and pembrolizumab are approved for treating platinum-refractory
recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Physicians …